BOSTON– Ibex Medical Analytics said it is accelerating its global growth in AI-powered pathology, announcing a leadership transition and expanding its footprint in biopharma and clinical markets worldwide.
The company named Yair Heller as Chief Executive Officer, effective immediately. Heller previously served as Chief Operating Officer. Co-founder Joseph Mossel will shift his focus to leading strategic growth initiatives, including the company’s rapidly expanding biopharma division and U.S. clinical operations.
“Ibex has been built on a strong foundation and is entering 2026 with tremendous momentum and a clear path to scaling our platform globally,” Heller said. “As we scale, we will continue delivering the most accurate and reliable tools for pathologists to help improve patient care, while also leveraging our platform to accelerate drug development pipelines and improve evidence quality worldwide.”
Ibex reported strong commercial momentum, including new clinical deployments with major laboratory networks in Europe and the United States, as well as expanded adoption by existing customers. The company said these partnerships reflect a growing global shift toward AI-powered pathology as a standard tool for cancer detection and diagnosis.
The company said it doubled the total number of pathology cases processed on its platform for the second consecutive year, expanded its customer base by more than 70 percent, and tripled the number of new live applications in 2025 compared with the prior year.
“Ibex enables us to deliver a new level of diagnostic precision, moving confidently to accurately diagnose more patients,” said Derek C. Welch, M.D., President and Chief Medical Officer at PathGroup. “Ibex strengthens our ability to support clinicians with timely, high-confidence results, and positions us to scale that impact as demand continues to grow.”
At the same time, Ibex said it is accelerating its expansion into life sciences under Mossel’s leadership. The company is enhancing its platform to support drug development, from biomarker assessment and clinical trial optimization through regulatory approval and clinical deployment.
A key focus of the biopharma strategy is the precise quantification of immunohistochemistry-based biomarkers, which are critical to the development of antibody-drug conjugates. Ibex said its computational scoring capabilities allow biopharma partners to improve patient selection, strengthen clinical evidence, and bridge the gap between clinical validation and real-world use.
“Leading Ibex as CEO has been one of the great privileges of my career, and I’m incredibly proud of what we’ve built so far,” Mossel said. “I have the utmost confidence in Yair’s leadership to drive our next phase of growth. With the company in such capable hands, I am thrilled to now focus my energy on our growing biopharma business. We have a unique opportunity to help bring life-saving treatments to market faster.”
